The stories have intensified growing concerns that the risk of NAION may not be limited to any single GLP-1 medication
Limited safety and efficacy data for research peptides creates uncertainty about their appropriate use and potential risks
Quality of Life : Sustained improvements in obesity-related comorbidities including obstructive sleep apnea, osteoarthritis symptoms, and overall quality of life measures
That means the first line of defense for age-related greying is to (1) reduce any unnecessary free radical activity, and (2) increase endogenous and exogenous antioxidant levels mainly through a diet that is nutrient replete, avoidant of inflammatory foods, and avoidant of a calorie deficit
However, compounded versions may carry additional risks due to quality variability
With Transcend, Lilly had a full picture of data, to the point that they published the data in The Lancet, but the trial was only 40 weeks long and multiple endpoints including A1c, weight loss and other markers havent quite hit the full potential of the drug for diabetics so were left with questions on what happens when you take it for a longer term